Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.
from Front page feed https://ift.tt/3anrvMV
from Front page feed https://ift.tt/3anrvMV
Comments
Post a Comment